Susan Chang
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Susan Chang sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Susan Chang: 5 sponsored US clinical trials, 2 recruiting.
Susan Chang sponsors 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Recurrent World Health Organization (WHO) Grade II Glioma, with 1 trials.
Upper-quartile sponsor footprint
Susan Chang sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
NCT04540107
Hyperpolarized Imaging in Diagnosing Participants With Glioma
NCT03739411
Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma
NCT04019002
68Ga-citrate PET/MR Imaging for Glioma
NCT03335280
Everolimus in Treating Patients With Recurrent Low-Grade Glioma
NCT00823459
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
What is open in the Susan Chang pipeline
2 recruiting of 5 indexed (40% open); 1 completed (20%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Recurrent World Health Organization (WHO) Grade II Glioma (1 trial), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Susan Chang: open-pipeline peers nationwide
Peers matched on 5 registered trials and 40% open enrollment, not the therapeutic-area sidebar.
Susan Chang sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 40% open enrollment (± trial volume)
- Ad scientiam · 40% recruiting · 5 trials
- Alto Neuroscience · 40% recruiting · 10 trials
- Bonafide Health · 40% recruiting · 5 trials
- Brooks Rehabilitation · 40% recruiting · 5 trials
Related
What to do with this Susan Chang page
5 registered trials is a research-attention snapshot, not an endorsement of Susan Chang or any single study.
- 2 of Susan Chang's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Recurrent World Health Organization (WHO) Grade II Glioma is the condition Susan Chang studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Recurrent World Health Organization (WHO) Grade II Glioma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Susan Chang pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.